Paper39006147
Cross talk between genetics and biochemistry in the pathogenesis of hepatocellular carcinoma.
Ucdal M and 2 others. Hepatol Forum, 2024. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Cross talk between genetics and biochemistry in the pathogenesis of hepatocellular carcinoma. Papers, record 39006147. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39006147
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Cross talk between genetics and biochemistry in the pathogenesis of hepatocellular carcinoma.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References115
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27100897 | MicroRNA-92b promotes hepatocellular carcinoma progression by targeting Smad7 and is mediated by long non-coding RNA XIST. | Cell Death Dis | 2016 | https://conductscience.org/library/papers/27100897 | PubMed |
| 2 | 26655911 | Stratification of Hepatocellular Carcinoma Patients Based on Acetate Utilization. | Cell Rep | 2015 | https://conductscience.org/library/papers/26655911 | PubMed |
| 3 | 25822088 | Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. | Nat Genet | 2015 | https://conductscience.org/library/papers/25822088 | PubMed |
| 4 | 22811581 | Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22811581 | PubMed |
| 5 | 26893654 | Prognostic significance of serum insulin-like growth factor-1 in patients with hepatocellular carcinoma following transarterial chemoembolization. | Exp Ther Med | 2016 | https://conductscience.org/library/papers/26893654 | PubMed |
| 6 | 28141967 | Telomerase Mechanism of Telomere Synthesis. | Annu Rev Biochem | 2017 | https://conductscience.org/library/papers/28141967 | PubMed |
| 7 | 17487939 | Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations. | J Pathol | 2007 | https://conductscience.org/library/papers/17487939 | PubMed |
| 8 | 32194906 | LncRNA FLJ33360 accelerates the metastasis in hepatocellular carcinoma by targeting miRNA-140/MMP9 axis. | Am J Transl Res | 2020 | https://conductscience.org/library/papers/32194906 | PubMed |
| 9 | 30061739 | Molecular therapies and precision medicine for hepatocellular carcinoma. | Nat Rev Clin Oncol | 2018 | https://conductscience.org/library/papers/30061739 | PubMed |
| 10 | 32173197 | Lead discovery, chemical optimization, and biological evaluation studies of novel histone methyltransferase SET7 small-molecule inhibitors. | Bioorg Med Chem Lett | 2020 | https://conductscience.org/library/papers/32173197 | PubMed |
| 11 | 28978124 | SLC2A2 (GLUT2) as a novel prognostic factor for hepatocellular carcinoma. | Oncotarget | 2017 | https://conductscience.org/library/papers/28978124 | PubMed |
| 12 | 26872014 | MicroRNA-361-5p Inhibits Cancer Cell Growth by Targeting CXCR6 in Hepatocellular Carcinoma. | Cell Physiol Biochem | 2016 | https://conductscience.org/library/papers/26872014 | PubMed |
| 13 | 35406630 | Metabolic Reprogramming and Its Relationship to Survival in Hepatocellular Carcinoma. | Cells | 2022 | https://conductscience.org/library/papers/35406630 | PubMed |
| 14 | 29749382 | microRNA-501-3p suppresses metastasis and progression of hepatocellular carcinoma through targeting LIN7A. | Cell Death Dis | 2018 | https://conductscience.org/library/papers/29749382 | PubMed |
| 15 | 29621773 | MicroRNA-214-5p Inhibits the Invasion and Migration of Hepatocellular Carcinoma Cells by Targeting Wiskott-Aldrich Syndrome Like. | Cell Physiol Biochem | 2018 | https://conductscience.org/library/papers/29621773 | PubMed |
| 16 | 9132148 | Oxidative phosphorylation and F(O)F(1) ATP synthase activity of human hepatocellular carcinoma. | Biochem Mol Biol Int | 1996 | https://conductscience.org/library/papers/9132148 | PubMed |
| 17 | 23764751 | Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma. | Br J Cancer | 2013 | https://conductscience.org/library/papers/23764751 | PubMed |
| 18 | 25647261 | MiR-32 induces cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting PTEN. | Tumour Biol | 2015 | https://conductscience.org/library/papers/25647261 | PubMed |
| 19 | 28553614 | Emerging Role of the Pentose Phosphate Pathway in Hepatocellular Carcinoma. | Front Oncol | 2017 | https://conductscience.org/library/papers/28553614 | PubMed |
| 20 | 21562580 | Cell-free nucleic acids as biomarkers in cancer patients. | Nat Rev Cancer | 2011 | https://conductscience.org/library/papers/21562580 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 39557956 | High expression of BBOX1 in paracancerous tissue is associated with poor prognosis in hepatocellular carcinoma patients. | Sci Rep | 2024 | https://conductscience.org/library/papers/39557956 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39006147
GET https://conductscience.org/api/papers/v1/39006147/references?page=2